AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3233896
Drug: Intravenous piggyback
RxNorm normalized name: intravenous piggyback set MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous piggyback method
Trial: 23669515
Drug: FITNET (Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FITNET (Internet-based cognitive behavioral therapy)
Trial: 21989146
Drug: LOAD-10 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LOAD-10 therapy (levofloxacin 250 mg, omeprazole 40 mg, nitazoxanide 500 mg twice daily, doxycycline 100 mg) for 10 days
Trial: 21989146
Drug: LOAD-7 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOAD-7 therapy (levofloxacin 250 mg, omeprazole 40 mg, nitazoxanide 500 mg twice daily, doxycycline 100 mg) for 7 days
Trial: 21989146
Drug: Combined LOAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined LOAD therapies
Trial: 21989146
Drug: LAC therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg) for 10 days
Trial: 16470745
Drug: Paclitaxel, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel, 200 mg/m² IV, every 21 days for a minimum of four cycles
Trial: 11588321
Drug: abciximab (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (0.25 mg/kg bolus before the lesion was crossed with guidewire and 0.125 micro. kg(‐1). min(‐1) infusion for 12 hours)
Trial: 7862710
Drug: Naloxone (0.01,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.01, 0.1, 1.0 mg/70 kg)
Trial: 7862710
Drug: Naloxone (1.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (1.0, 3.0, 10 mg/70 kg)
Trial: 2512175
Drug: Rhein (diacetyl‐rhein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhein (diacetyl‐rhein 50 mg b.d. for 5 days)
Trial: 8257478
Drug: 5'-MTHF (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-MTHF (50 mg/day p.o.)
Trial: 8257478
Drug: Trazodone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (100 mg/day p.o.)
Trial: 3582469
Drug: Urapidil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil infusion at 10 mg/h for 4 h
Trial: 3582469
Drug: Urapidil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil infusion at 2.5 mg/h for 4 h
Trial: 3582469
Drug: Urapidil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil infusion at 5 mg/h for 4 h
Trial: 3582469
Drug: Urapidil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil infusion at 10 mg/h followed by a 60 mg capsule after 2 h
Trial: 23176073
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg rasagiline
Trial: 23176073
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg rasagiline and 1.5 mg pramipexole
Trial: 20885016
Drug: Pentazocine 0.5
RxNorm normalized name: naloxone-pentazocine 0.5 mg-50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 0.5 mg·kg(‐1) 5 min prior to fentanyl
Trial: 8776692
Drug: Standard osmolality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard osmolality feeding (1200 mOsmol/L)
Trial: 8776692
Drug: High osmolality
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High osmolality feeding (1700 mOsmol/L)
Trial: 1626958
Drug: Isotretinoin (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (approximately 0.14 mg/kg per day for 3 years)
Trial: 6437509
Drug: Loperamide 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 0.8 mg/kg/24 h
Trial: 6437509
Drug: Loperamide 0.4
RxNorm normalized name: loperamide 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 0.4 mg/kg/24 h
Trial: 6437509
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus oral rehydration therapy
Trial: 29421020
Drug: High-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow oxygen (10-15 L/min)
Trial: 20970847
Drug: Aspirin (≥75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (≥75 mg daily)
Trial: 20970847
Drug: Aspirin (75-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75-300 mg daily)
Trial: 20970847
Drug: Aspirin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (30 mg vs 283 mg daily)
Trial: 17284755
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: 30 g dry weight of an iron-fortified cereal porridge and a separate dose of an aqueous multivitamin (MV) supplement
Trial: 17284755
Drug: ZnSuppl group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnSuppl group: same porridge and MV with 3 mg Zn added to the supplement dose
Trial: 17284755
Drug: ZnFort group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnFort group: porridge with added zinc (150 mg/kg dry weight) and MV without zinc
Trial: 9049794
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B Plak Control electric toothbrush
Trial: 8457038
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 micrograms twice daily for 14 days)
Trial: 11381581
Drug: All implants
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All implants
Trial: 29189275
Drug: US-assisted LSGB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-assisted LSGB with 10 mL of 0.25% levobupivacaine
Trial: 29189275
Drug: FL-guided LSGB
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FL-guided LSGB with 10 mL of 0.25% levobupivacaine
Trial: 24717789
Drug: GSK2190915 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 200 mg
Trial: 18441680
Drug: Thiotorpium bromide
RxNorm normalized name: Potassium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiotorpium bromide (TB) 18 mcg/day for one year, almitrine 10 mg/kg/day for 3 months, and an 8 week course of pulmonary rehabilitation (PR)
Trial: 15029983
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral methadone tablet
Trial: 15029983
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg sublingual buprenorphine tablet
Trial: 10966839
Drug: GP‐C (glycosaminoglycan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP‐C (glycosaminoglycan polypeptide association complex) 2 ml intramuscularly, 10 courses over 5 years (15 injections per course, twice weekly)
Trial: 22051419
Drug: Levosimendan infusion
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan infusion at a dose of 0.1 μg/kg/min with an initial bolus (12 μg/kg for 10 minutes) after anesthesia induction (Group C)
Trial: 22051419
Drug: Prophylactic IABP
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic IABP one day before surgery and levosimendan infusion (Group B)
Trial: 21138627
Drug: Without anti-viral
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Without anti-viral therapy (study group)
Trial: 21138627
Drug: Lamivudine therapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine therapy (control group)
Trial: 18207017
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient (MMN) supplementation in anaemic women (Hb <110 g/L)
Trial: 15985134
Drug: L‐aspartate and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐aspartate and L‐glutamate-enriched cardioplegia (13 mmol/L)
Trial: 10391395
Drug: Metformin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (250 mg three times daily for 12 months)
Trial: 8683251
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional chemotherapy)
Trial: 8683251
Drug: Early high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early high-dose therapy (HDT)
Trial: 6144125
Drug: Haloperidol 1
RxNorm normalized name: haloperidol 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 1 mg, 3 mg, and 6 mg
Trial: 6144125
Drug: Propericiazine 10
RxNorm normalized name: propericiazine 10 MG per 5 ML Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propericiazine 10 mg and 30 mg
Trial: 6144125
Drug: Propericiazine 60
RxNorm normalized name: Propericiazine
DrugBank: Periciazine (DB01608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propericiazine 60 mg
Trial: 30681754
Drug: Opicapone 50
RxNorm normalized name: opicapone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 50 mg (open-label phase)
Trial: 30383670
Drug: Microecological preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microecological preparation supplementation
Trial: 25036712
Drug: Open-label levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open-label levodopa treatment
Trial: 9199818
Drug: rt-PA, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA, 100 mg over 2 h (Group A)
Trial: 9199818
Drug: rt-PA, 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA, 0.6 mg/kg, maximum dose 50 mg, over 15 min (Group B)
Trial: 3900392
Drug: Amflutizole 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amflutizole 500 mg dosage
Trial: 28842727
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 (loading dose of 540,000 IU and five monthly maintenance doses of 90,000 IU)
Trial: 25813216
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER 15 mg
Trial: 25813216
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER 30 mg
Trial: 25813216
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER 45 mg
Trial: 25813216
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER 60 mg
Trial: 25813216
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER 90 mg
Trial: 25813216
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER (all doses)
Trial: 17279096
Drug: Topical phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical phenytoin solution (5 mg/ml)
Trial: 15476909
Drug: Subhypnotic-dose propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subhypnotic-dose propofol 1.0 mg/kg per hour combined with dexamethasone 8 mg
Trial: 15476909
Drug: Subhypnotic-dose propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subhypnotic-dose propofol 1.0 mg/kg per hour alone
Trial: 8605519
Drug: 6% glucose/sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% glucose/sucrose solution
Trial: 8605519
Drug: Placebo (artificially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (artificially flavored and sweetened solution)
Trial: 821050
Drug: Cooling treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling treatment with 'Cryogel'
Trial: 28576892
Drug: Traditional and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional and complementary medicine interventions (ear and body acupuncture, aromatherapy) in combination with nicotine replacement therapy (NRT) and counselling
Trial: 28576892
Drug: Conventional cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional cessation methods (nicotine replacement therapy (NRT), counselling)
Trial: 25420534
Drug: Armillarisin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armillarisin A 10 mg enema in 100 ml saline
Trial: 25420534
Drug: Armillarisin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armillarisin A 10 mg and dexamethasone 5 mg enema in 100 ml saline
Trial: 25420534
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg enema in 100 ml saline
Trial: 17012628
Drug: Bosentan plus
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan plus inhaled iloprost (combination group)
Trial: 11692092
Drug: Intranasal heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal heparin
Trial: 9113630
Drug: High-AA diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-AA diet (1.5 g/d of AA in the form of a triglyceride containing 50% AA)
Trial: 9113630
Drug: Low-AA diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-AA diet (210 mg/d of AA)
Trial: 18982335
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tramadol (Group T)
Trial: 18982335
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tramadol with 0.5 mg kg(‐1) ketamine (Group TK)
Trial: 18982335
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg ropivacaine (Group R)
Trial: 18982335
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg ropivacaine with 0.5 mg kg(‐1) ketamine (Group RK)
Trial: 17907228
Drug: Ganoderma lucidum
RxNorm normalized name: GANODERMA LUCIDUM STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganoderma lucidum (4 gm) and San Miao San (2.4 gm) daily
Trial: 11907486
Drug: Saquinavir 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir 50 mg/kg tid alone
Trial: 11907486
Drug: Saquinavir 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir 50 mg/kg tid plus nelfinavir 30 mg/kg tid
Trial: 11907486
Drug: Saquinavir (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir (any dosage)
Trial: 10096977
Drug: Heparin-coated cardiopulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated cardiopulmonary bypass equipment
Trial: 2082316
Drug: Ketorolac active/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac active/heparin dummy
Trial: 2082316
Drug: Ketorolac active/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac active/heparin active
Trial: 2082316
Drug: Heparin active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin active
Trial: 2082316
Drug: Ketorolac dummy/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac dummy/heparin active
Trial: 29374963
Drug: Unified Protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children (UP‐C)
Trial: 25833066
Drug: Conventional inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional inhaled corticosteroid (ICS)
Trial: 26060627
Drug: Emotional intelligence
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Emotional intelligence training (12 sessions, 50 minutes each, twice a week)
Trial: 21372765
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily 1 sachet of probiotic + high-fibre diet (Group B)
Trial: 21372765
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily 2 sachets of probiotic + high-fibre diet (Group C)
Trial: 17348994
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (TC) cream applied once daily for 8 weeks
Trial: 17348994
Drug: Hydroquinone (HQ)
RxNorm normalized name: Hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroquinone (HQ) cream applied twice daily for 8 weeks
Trial: 17348994
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (TC) cream and Hydroquinone (HQ) cream
Trial: 17190958
Drug: Oxcarbazepine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (600 mg BID)
Trial: 17190958
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without oxcarbazepine
Trial: 14567803
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine 30 ml instilled into the pelvic cavity and over the diaphragmatic vault (Group A)
Trial: 14567803
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine 30 ml instilled (Group B)
Trial: 14567803
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 30 ml instilled (Group C)
Trial: 14567803
Drug: No intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intraperitoneal agent (Group D)
Trial: 10469856
Drug: Routine hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine hemodialysis (135-140 mEq/L sodium bath)
Trial: 10469856
Drug: Hypernatric hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypernatric hemodialysis (150-155 mEq/L sodium bath)
Trial: 8740048
Drug: SDZ EAA
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SDZ EAA 494 single dose (1-50 mg)
Trial: 8740048
Drug: SDZ EAA
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SDZ EAA 494 multiple doses (25 mg once or twice daily for 1 week)
Trial: 1874211
Drug: Intrapleural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural bupivacaine (10 ml of 0.25% bupivacaine with 1:200,000 adrenaline every 8 h for 4 days)
Trial: 1874211
Drug: Intrapleural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural saline (10 ml normal saline every 8 h for 4 days)
Trial: 6577782
Drug: Gemfibrozil, 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil, 1,200 mg/day
Trial: 21574800
Drug: Medpor® wedge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medpor® wedge implant
Trial: 19687575
Drug: Manual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual physical therapy and exercise (MTEX)
Trial: 19687575
Drug: Electrophysical agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysical agents and exercise (EPAX)
Trial: 8409070
Drug: Flosequinan 50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosequinan 50, 100 or 150 mg daily (short-term administration)
Trial: 8409070
Drug: Flosequinan 50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosequinan 50, 100 or 150 mg daily (long-term administration after 8 weeks)
Trial: 3898833
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g in the morning and 2 g at night)
Trial: 29391385
Drug: Oral nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nitazoxanide
Trial: 12711404
Drug: Interval medication
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval medication
Trial: 12742493
Drug: Sirolimus (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (2 mg/d) in one-haplotype living-related kidney allografts
Trial: 12742493
Drug: Sirolimus (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (2 mg/kg per day) in one-haplotype living-related kidney allografts
Trial: 12742493
Drug: Sirolimus (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (2 mg/day) in fully mismatched living kidney allografts
Trial: 12742493
Drug: Sirolimus (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (target trough concentrations 8-12 ng/mL) in high-risk black ethnicity recipients
Trial: 12742493
Drug: Sirolimus (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (target trough concentrations 15-20 ng/mL) in high-risk black ethnicity recipients
Trial: 10321420
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin (100 mg)
Trial: 10321420
Drug: Intravenous moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous moxifloxacin (100 mg, 60-minute infusion)
Trial: 10321420
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and IV formulations